Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment.

McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF, Sorant AJ, Papanicolaou GJ, Laje G, Fava M, Trivedi MH, Wisniewski SR, Manji H.

Am J Hum Genet. 2006 May;78(5):804-14.

2.

Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopram.

Choi MJ, Kang RH, Ham BJ, Jeong HY, Lee MS.

Neuropsychobiology. 2005;52(3):155-62.

PMID:
16127283
3.

Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort.

Paddock S, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJ, Lipsky R, Wisniewski SR, Manji H, McMahon FJ.

Am J Psychiatry. 2007 Aug;164(8):1181-8.

PMID:
17671280
4.

Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment.

Horstmann S, Lucae S, Menke A, Hennings JM, Ising M, Roeske D, Müller-Myhsok B, Holsboer F, Binder EB.

Neuropsychopharmacology. 2010 Feb;35(3):727-40. doi: 10.1038/npp.2009.180.

5.

HTR2A gene variation is involved in antidepressant treatment response.

Lucae S, Ising M, Horstmann S, Baune BT, Arolt V, Müller-Myhsok B, Holsboer F, Domschke K.

Eur Neuropsychopharmacol. 2010 Jan;20(1):65-8. doi: 10.1016/j.euroneuro.2009.08.006.

PMID:
19758789
6.

Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response.

Binder EB, Owens MJ, Liu W, Deveau TC, Rush AJ, Trivedi MH, Fava M, Bradley B, Ressler KJ, Nemeroff CB.

Arch Gen Psychiatry. 2010 Apr;67(4):369-79. doi: 10.1001/archgenpsychiatry.2010.18.

PMID:
20368512
7.

Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression.

Hu XZ, Rush AJ, Charney D, Wilson AF, Sorant AJ, Papanicolaou GJ, Fava M, Trivedi MH, Wisniewski SR, Laje G, Paddock S, McMahon FJ, Manji H, Lipsky RH.

Arch Gen Psychiatry. 2007 Jul;64(7):783-92.

PMID:
17606812
8.

Common genetic variation in the indoleamine-2,3-dioxygenase genes and antidepressant treatment outcome in major depressive disorder.

Cutler JA, Rush AJ, McMahon FJ, Laje G.

J Psychopharmacol. 2012 Mar;26(3):360-7. doi: 10.1177/0269881111434622.

PMID:
22282879
9.

Pharmacogenetics studies in STAR*D: strengths, limitations, and results.

Laje G, Perlis RH, Rush AJ, McMahon FJ.

Psychiatr Serv. 2009 Nov;60(11):1446-57. doi: 10.1176/appi.ps.60.11.1446.

10.

TPH1, MAOA, serotonin receptor 2A and 2C genes in citalopram response: possible effect in melancholic and psychotic depression.

Arias B, Fabbri C, Gressier F, Serretti A, Mitjans M, Gastó C, Catalán R, De Ronchi D, Fañanás L.

Neuropsychobiology. 2013;67(1):41-7. doi: 10.1159/000343388.

PMID:
23221997
11.

5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients.

Kato M, Zanardi R, Rossini D, De Ronchi D, Okugawa G, Kinoshita T, Colombo C, Serretti A.

Psychiatry Res. 2009 May 15;167(1-2):97-105. doi: 10.1016/j.psychres.2007.12.012.

PMID:
19361869
12.

Genetic variation in HTR2A influences serotonin transporter binding potential as measured using PET and [11C]DASB.

Laje G, Cannon DM, Allen AS, Klaver JM, Peck SA, Liu X, Manji HK, Drevets WC, McMahon FJ.

Int J Neuropsychopharmacol. 2010 Jul;13(6):715-24. doi: 10.1017/S1461145709991027.

13.

SLC6A4 polymorphisms and age of onset in late-life depression on treatment outcomes with citalopram: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report.

Shiroma PR, Drews MS, Geske JR, Mrazek DA.

Am J Geriatr Psychiatry. 2014 Nov;22(11):1140-8. doi: 10.1016/j.jagp.2013.02.012.

14.

A genomewide association study of citalopram response in major depressive disorder.

Garriock HA, Kraft JB, Shyn SI, Peters EJ, Yokoyama JS, Jenkins GD, Reinalda MS, Slager SL, McGrath PJ, Hamilton SP.

Biol Psychiatry. 2010 Jan 15;67(2):133-8. doi: 10.1016/j.biopsych.2009.08.029.

15.

Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder.

Perlis RH, Fijal B, Adams DH, Sutton VK, Trivedi MH, Houston JP.

Biol Psychiatry. 2009 May 1;65(9):785-91. doi: 10.1016/j.biopsych.2008.10.002.

PMID:
19095219
16.
17.

Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies.

GENDEP Investigators.; MARS Investigators.; STAR*D Investigators..

Am J Psychiatry. 2013 Feb;170(2):207-17. doi: 10.1176/appi.ajp.2012.12020237.

PMID:
23377640
18.

ABCB1 Genetic Effects on Antidepressant Outcomes: A Report From the iSPOT-D Trial.

Schatzberg AF, DeBattista C, Lazzeroni LC, Etkin A, Murphy GM Jr, Williams LM.

Am J Psychiatry. 2015 Aug 1;172(8):751-9. doi: 10.1176/appi.ajp.2015.14050680.

PMID:
25815420
19.

Interaction of serotonin-related genes affects short-term antidepressant response in major depressive disorder.

Lin E, Chen PS, Chang HH, Gean PW, Tsai HC, Yang YK, Lu RB.

Prog Neuropsychopharmacol Biol Psychiatry. 2009 Oct 1;33(7):1167-72. doi: 10.1016/j.pnpbp.2009.06.015.

PMID:
19560507
20.

SLC6A4 variation and citalopram response.

Mrazek DA, Rush AJ, Biernacka JM, O'Kane DJ, Cunningham JM, Wieben ED, Schaid DJ, Drews MS, Courson VL, Snyder KA, Black JL 3rd, Weinshilboum RM.

Am J Med Genet B Neuropsychiatr Genet. 2009 Apr 5;150B(3):341-51. doi: 10.1002/ajmg.b.30816.

Items per page

Supplemental Content

Support Center